News Archive

SomaLogic and Otsuka scientists publish paper describing therapeutic potential of novel SOMAmer reagent for rheumatoid arthritis

In a “Fast Track” article published in the journal Nucleic Acid Therapeutics, researchers from SomaLogic and Otsuka Pharmaceutical describe a series of studies that demonstrate that treatment with a novel Slow Off-rate Modified Aptamer (SOMAmer) molecule can significantly delay the onset and reduce the severity of rheumatoid arthritis in a cynomolgus monkey model of the disease.

read more

SomaLogic named “Company of the Year” at Colorado BioScience Association’s 2015 Awards Dinner

SomaLogic was recognized as “Company of the Year” by the Colorado BioScience Association at its 12th Annual Awards Dinner in Denver, CO, on November 12, 2015. SomaLogic was cited for developing “a new proteomics technology with a mission to leverage its proprietary technology to discover, develop and commercialize revolutionary new life science research tools and breakthrough clinical diagnostic products that will transform healthcare.”

read more

SomaLogic launches new, larger commercial version of SOMAscan assay

SomaLogic announced today that the latest version of its proprietary SOMAscan proteomics assay, which now measures 1,310 protein analytes, is commercially available to the life science research community. This new version, called “SOMAscan Assay 1.3k,” is replacing the current 1,129 protein analytes version, but without an increase in price.

read more